Shares of Johnson & Johnson (JNJ) rose 1.5% on Friday after Janssen, a JNJ company, disclosed positive data from the Phase 3b COSMOS trial of TREMFYA. TREMFYA is the first-of-its-kind selective interleukin (IL)-23 inhibitor therapy, approved in the U.S. for moderate to severe plaque psoriasis and active psoriatic arthritis (PsA ) irrespective of prior tumor necrosis factor inhibition (TNFi) exposure. The trial was designed to evaluate the efficacy and safety of TREMFYA in 285 patients with active PsA and intolerance to TNFi therapy. The data demonstrated that the COSMOS study met its primary endpoint, with a significantly higher proportion of TREMFYA-treated patients achieving ACR20 response versus the placebo at week 24. Furthermore, response rates continued to improve during the first year, with 57.
https://www.tipranks.com/news/johnson-johnson-announces-data-from-phase-3b-cosmos-trial-of-tremfya?utm_source=advfn.com&utm_medium=referral
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Dez 2021 até Jan 2022 Click aqui para mais gráficos Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Jan 2021 até Jan 2022 Click aqui para mais gráficos Johnson and Johnson.